

NIH Long-Term Planning Initiative NCI Response: the BSC Perspective

Louis M. Weiner, MD

Director, Georgetown Lombardi Comprehensive
Cancer Center

Chair, NCI BSC for Clinical Sciences and
Epidemiology

The NCI Intramural Research Program

- Vibrant research culture
- Fewer academic encumbrances – e.g., teaching
- Less time spent writing grants
- Smaller labs than in extramural community
- Vibrant shared resources and access to cutting edge technology platforms
- Paralyzing governmental bureaucracy
 - Travel restrictions
 - Difficult access to exciting drugs for clinical trials
 - No coffee

Dynamic Remodeling of the NCI IRP

- Number of PIs reduced from 375 in 2002 to 307 in 2014
- Number of Branches/Labs reduced from 64 in 2011 to 56 in 2014
- Reorganization of branches
- Reorganization of clinical services
- Maintenance of high impact
 - Multiple drugs and devices moved into practice during the past 10 years
 - Exceptional discoveries
 - Constant stream of high impact papers

- BSC advises and supports CCR and DCEG Leadership
- Periodic review of branches/PIs
- Totality of research program is evaluated (e.g., not project-specific)
- Rigorous review process with site visits led by BSC members
 - Criteria – Quality, impact, “uniqueness”, mission
 - Typical descriptors
 - Merit: **Outstanding**, Excellent, Very Good
 - Recommendation: Continuation, Expansion, Contraction, Closure, Early Re-Review

BSC and IRP Leadership See Opportunities for Greater Impact

- **Make better use of the Clinical Center**
 - Increase trans-NIH and intramural-extramural collaborations
 - Assure that the priorities of the Clinical Center can rapidly respond to changing research opportunities
- **Identify and nurture key initiatives that leverage the unique intellectual resources and technology available to the NCI IRP**
- **Focus on “bottom-up” as opposed to “top-down” identification and prioritization of key initiatives**

Role of the BSC in Responding to NIH Director's Long Term Planning Initiative

- BSC representatives present at initial presentations of concepts for NCI response
- Feedback provided, leading to five proposals that
 - Respond to the goals of the initiative
 - Identify areas for NCI IRP resource prioritization
 - Advance translational science based on exceptional accomplishments in basic science
 - Capitalize on distinct NCI IRP capabilities (e.g., have scope and depth that cannot be easily replicated in academia or industry)
- Results shared with and responses solicited from broader BSC community

Key Attributes of Each Initiative

- **The Microbiota and the Human Metaorganism In Cancer Biology and Medicine**
 - Exciting new science
 - Multi-institute; leverages IRP/Frederick National Lab genomics capabilities
- **Development of Cell-based Therapies In the IRP**
 - Exciting, home-grown science
 - IRP and Clinical Center well suited to address complexity
 - Leverages IRP's exceptional capabilities in immunology
- **National Program for Natural Products Discovery**
 - Distinctive resource unavailable elsewhere
 - Facilitates trans-NIH and extramural collaborations

Key Attributes of Each Initiative

- Precision Medicine
 - Leverages NCI multi-platform genomics capabilities
 - Connection with clinical center – especially as applied to rare diseases
 - Connection with NCI Division of Cancer Treatment & Diagnosis to facilitate large-scale extramural collaborations
- The Human RNA Project
 - Exciting area of basic science with new insights that require comprehensive approach
 - Trans-NIH and extramural collaborative opportunities

Discussion